thelial function, and microvascular rarefaction (22) . This later form of reverse angiogenesis may be responsible for the microvascular deterioration linking atherosclerosis with different forms of dementia (23) . Conventional cardiovascular risk factors, degenerative brain disease, and Alzheimer's disease. Links between cardiovascular risk factors, vascular disease, and aging (24) continued to be documented. In models adjusted for age, ethnicity, marital status, and education, increments in the Framingham risk score were associated with faster decline in cognitive function in both middle-aged men and women without apparent CVD (25) . In addition, documented peripheral vascular disease was highlighted as a marker for cognitive impairment and progression to dementia (26) .
Early Detection and Risk Stratification
Conventional risk factors. From the INTERHEART study, scores with and without laboratory-based variables for the prediction of myocardial infarction were developed and validated in a multiethnic and multigeographic population (27) . Both the Framingham and the Reynolds scores were able to predict incidence and progression of coronary artery calcification similarly (28) .
Across the world, secondhand smoking directly caused Ͼ600,000 deaths, more than one-half related to CHD (29) . Moreover, parental smoking was linked to higher blood pressure and lower high-density lipoprotein (HDL) cholesterol in young children (30, 31) . For unclear reasons, the relative risk of smoking-related CHD was 25% higher in women after adjusting for other confounders (32) . A higher body mass index in adolescence (even within the range considered normal) was independently associated with CHD in adulthood (33) . However, the risk profiles of adults who were obese during childhood and then became nonobese were comparable to those of adults who were never obese (34) . Previous research identified obesity as an independent risk factor for CVD, but prospective data from Ͼ220,000 apparently healthy persons demonstrated no incremental ability of either the body mass index, waist circumference, or waist-to-hip ratio over conventional risk factors to predict incident CVD (35) . Conversely, parental history of myocardial infarction (36) or cardiorespiratory fitness (37) may provide additive prognostic value over standard risk factors. Regarding blood lipids, a metaanalysis of 12 studies including nearly 23,000 events indicated better predictive ability of apolipoprotein B than either low-density lipoprotein (LDL) or non-HDL choles- The Year in Atherothrombosis terol levels, and suggested that more events could be prevented by targeting this lipid fraction (38) . Serum and genetic biomarkers. Despite the failure of prior trials using homocysteine-lowering therapies to reduce events, a potential role for homocysteinemia in risk stratification in asymptomatic persons was supported by combined data from 2 large cohorts (39) . Both positive and negative findings were reported regarding the ability of C-reactive protein (CRP) to independently predict cardiovascular outcomes in asymptomatic subjects (40,41). Similarly, prior studies have not shown clear relationships between CRP and atherosclerosis burden; an investigation using computed tomography (CT) coronary angiography in asymptomatic subjects reported independent associations of elevated CRP with mixed coronary plaques, but not other subtypes (42) . In a 9-year prospective study of 3,649 men aged 60 to 79 years, N-terminal pro-brain natriuretic peptide but not CRP demonstrated incremental value over traditional risk factors for the prediction of major CVD events in the settings of both primary and secondary prevention (43) . Finally, quantification of troponin T plasma levels with high-sensitivity assays was confirmed to independently predict cardiovascular events in apparently healthy persons (44) . A study involving Ͼ80,000 adoptees suggested that transmission of CHD from parents to offspring is more strongly related to genetic than to familial environmental factors (45) . Meta-analyses of genome-wide association studies identified novel loci linked to subclinical atherothrombosis and clinical CHD (46 -48) . Importantly, only few of these newly recognized variants relate to known risk factors, indicating potentially unidentified pathways in the pathogenesis of atherothrombosis. Another genome-wide association study including 15 population-based cohorts identified multiple genetic variants (mostly related to immune and metabolic regulatory pathways) associated with increased CRP levels but not to higher CHD risk (49) . Invasive imaging. In nearly 3,500 patients enrolled in 7 serial intravascular ultrasound (IVUS) trials, concomitant peripheral artery disease was correlated with increased burden of coronary atherosclerosis, concentric remodeling, and atheroma progression (50) . IVUS plaque features were related to outcomes in the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study (51) . Nearly 700 patients with an acute coronary syndrome underwent triple-vessel IVUS and were followed up for a median of 3.4 years. Recurrent events (mostly readmissions) occurred in approximately 20% of the patients, and approximately 50% of these were related to nonculprit lesions. Large plaque burden, small luminal area, and presence of a thin-cap fibroatheroma on virtual histology were IVUS-based variables predictive of events from nonculprit lesions (Fig. 3) . Using optical coherence tomography, the median minimal cap thickness measured in vivo in ruptured plaques was 54 m in comparison with 80 m for nonruptured lesions. A value of Ͻ67 m was identified as the optimal cutoff to predict rupture, which is in close agreement with the value of Ͻ65 m derived from histopathology studies (52) . Noninvasive imaging. Data from the Framingham Offspring study revisited the potential of quantification of carotid intima-media thickness (CIMT) for risk stratification in primary prevention. The CIMT provided very modest additive information to the Framingham risk score, slightly improved by inclusion of plaque presence (53) . The CIMT, however, and as opposed to coronary calcification detected with CT, was not useful for further risk stratification in participants of the MESA (Multi-Ethnic Study of Atherosclerosis) trial who had low LDL cholesterol levels (Յ130 mg/dl) (54) . Selecting MESA participants with low LDL cholesterol and high CRP levels, such as those in the JUPITER (Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin) study, 74% of all CHD events occurred in the 25% of subjects with a calcium score Ͼ100, with an excellent outcome for the nearly 50% of participants with a score of zero (40). Nonetheless, in this and another large prospective study, coronary calcification was a substantially stronger predictor of outcomes than CRP in primary prevention, and CRP added no or marginal additional information to the calcium score (40,41). Regarding the prognostic value of coronary CT angiography, a meta-analysis of 18 studies and nearly 9,600 symptomatic participants indicated a 3.2% annual rate of myocardial infarction or death in the presence of obstructive disease versus 0.15% (p Ͻ 0.05) for a normal study (55) . Importantly, nonobstructive atherosclerosis on CT angiography also had a negative impact on mortality after accounting for conventional risk factors (56) . Magnetic resonance imaging (MRI) can depict intraplaque hemorrhage as areas of high signal intensity. A pathogenic role of this finding in cerebrovascular events was reinforced by an investigation demonstrating increased ipsilateral brain ischemia and microembolic activity in the presence of intraplaque bleeding (57) . Moreover, high signal intensity noted in carotid plaques (Fig. 4) was the strongest independent predictor of coronary events (hazard ratio [HR]: 3.2, 95% confidence interval [CI]: 1.9 to 5.6; p Ͻ 0.0001) in 217 patients with stable CHD followed up for mean of 38 months (58) . The feasibility of visualizing intracoronary thrombus in acute coronary syndromes with MRI was also reported (59). Molecular and experimental imaging. Serial ultrasonography using microbubbles was employed to successfully track changes in plaque neovascularization in experimental atherosclerosis (60) . Investigations using positron emission tomography demonstrated anti-inflammatory effects of pioglitazone on atherosclerotic plaques both in animal models (61) and in humans (62) . Another interesting ex vivo study indicated that tracer activity on positron emission tomography may reflect not only inflammatory burden but also hypoxia (63) . A pilot human study suggested that increased inflammation as determined by enhanced uptake of iron oxide ultrasmall superparamagnetic particles on MRI predicts rapid growth of abdominal aortic aneurysms (64) . In addition, iron oxide particles targeted with oxidationspecific antibodies could be detected within atherosclerotic lesions in mice (65) . Other MRI contrast agents with high affinity for matrix metalloproteinases or elastin were used to track changes in arterial remodeling in experimental models (66, 67) . Finally, a novel intravascular catheter was developed and validated for 2-dimensional in vivo near-infrared fluorescence imaging of increased protease activity in atherosclerotic plaques (68) .
Components of Ideal Cardiovascular Health

Prevention and Treatment
Adequacy of risk factor control. A study from Europe involving Ͼ7,500 patients without known CVD and at least 1 risk factor indicated that adequate risk factor control is achieved in Ͻ40% of persons (69) . Similarly, the multinational REACH (Reduction of Atherothrombosis for Continued Health Registry) study indicated that Ͻ60% of patients at high risk for or with established atherothrombosis reached Ն3 guideline-recommended risk factor targets (70) . In the United States, in patients with stable CHD undergoing percutaneous intervention, optimal medical therapy remains largely under-utilized (71) . Insufficient use of secondary prevention drugs could be particularly harmful for patients with peripheral arterial disease, who may go unrecognized (72) . Furthermore, secondary prevention is remarkably low across the world according to the multinational PURE (Prospective Urban Rural Epidemiological) study (73) . That is especially troublesome in middle-and low-income countries, which carry a large burden of CVD but where as many as 80% of patients may receive no preventive drugs at all (Fig. 5) . The Institute of Medicine's recommendations for promoting global cardiovascular health, with a particular emphasis on lower income countries, were summarized elsewhere (74) . Drug affordability and adherence. Improving drug availability and affordability is crucial for CVD control in 
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The Year in Atherothrombosis low-income countries (75) but is also very relevant in richer economies. A study from the United States randomized nearly 6,000 post-myocardial infarction patients to a standard prescription plan with associated out-of-pocket costs or to full coverage. Medication adherence was 4% to 6% higher, and patient spending was 26% lower (p Ͻ 0.001) in the group receiving complete coverage, without an increase in overall healthcare costs. This was associated with significant reductions in events in the full-coverage group (21.5% vs. 23.3%, HR: 0.89; p ϭ 0.03) (76) . It was estimated that a polypill (another potential approach to improve therapy affordability and adherence) containing aspirin, statin, angiotensin-converting enzyme inhibitor, and beta-blocker could reduce the 10-year incidence of CHD and stroke by 32% and 30%, respectively, in U.S. patients with prior CVD. A similar pill with a thiazide diuretic instead of a beta-blocker could reduce the same outcomes by 44% and 37%, respectively, if used by all U.S. adults Ն55 years old for primary prevention (77) . Nonpharmacologic and global interventions. Beyond pharmacologic approaches, inexpensive interventions may also bring large health rewards. Adherence to the Mediterranean diet reduces the risk for the metabolic syndrome and its individual components according to a meta-analysis of 50 studies (78). Even low-volume physical exercise (defined as 15 min per day or 90 min per week) was independently associated with a 20% reduction in cardiovascular mortality risk (79) . Yet higher impact may be expected by implementing policies that affect the population at large, from reductions in sodium in the food supply to development of walking/biking trails that promote healthier environments (80) . Statin therapy and dyslipidemia. Simulation studies suggested that inexpensive generic statins would be cost effective if primary prevention indications were expanded to persons with lower LDL cholesterol levels than currently recommended, or to moderate-risk or high-risk persons regardless of LDL cholesterol concentration (81, 82) . Measuring CRP and treating with rosuvastatin if Ͼ2 mg/dl (JUPITER-like strategy) was also deemed cost effective (83) . Nonetheless, statin therapy for patients with low LDL cholesterol but high CRP was put into question by a post-hoc analysis of the Heart Protection Study, the largest randomized trial to date of statin therapy versus placebo in patients with high vascular risk (many of them with known prior CVD) and that encompassed Ͼ4,500 events. The study found no evidence of relatively increased protection of simvastatin 40 mg daily for 5 years for patients with higher CRP levels. In fact, simvastatin provided comparable protective effects for patients with CRP levels Ͻ1 mg/dl (84 compared rosuvastatin 40 mg daily versus atorvastatin 80 mg daily for 2 years using IVUS-derived coronary atheroma as a primary endpoint. Despite lower LDL and higher HDL levels achieved with rosuvastatin, both regimens resulted in comparable atheroma volume reductions of approximately 1% (85) . The optimal approach to pharmacologically modulate the potentially atheroprotective effects of HDL cholesterol continued to be controversial. The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) study evaluated the effects of extended-release niacin versus placebo added on top of intensive statin therapy in 3,414 stable patients with established CVD, low LDL levels (median 74 mg/dl), median HDL concentrations of 35 mg/dl, and median triglyceride levels of 163 mg/dl (86) . Despite a 25% increase in HDL cholesterol and 31% and 14% reductions in triglycerides and LDL cholesterol levels, respectively, the trial was stopped prematurely after 3 years because of lack of efficacy of niacin to improve cardiovascular outcomes (Fig. 6 ). Whether these findings can be extrapolated to patients with acute syndromes or higher baseline levels of LDL cholesterol remains to be determined. Novel cholesteryl ester transfer protein inhibitors may raise HDL cholesterol without concomitant undesired increases in blood pressure. In the dal-PLAQUE (Safety and Efficacy of Dalcetrapib on Atherosclerotic Disease Using Novel Non-Invasive Multimodality Imaging) study, dalcetrapib did not show proatherogenic effects as demonstrated by MRI and positron emission tomography/CT when administered over 24 months to stable patients with high cardiovascular risk. Conversely, there was no evidence of reductions in arterial inflammation by raising HDL cholesterol with dalcetrapib (87) . Merely increasing HDL cholesterol may not lead to improved outcomes based on a large series of subjects ranging from healthy volunteers to patients with CHD, where reduced HDL cholesterol efflux 
Figure 6 Main Results of the AIM-HIGH Trial
In the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides) trial, addition of niacin to statin therapy (red line) when compared to placebo (black line) did not result in a reduction of the primary outcome (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptomdriven coronary or cerebral revascularization). No. ϭ number. Reproduced with permission from the AIM-HIGH Investigators (86).
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The Year in Atherothrombosis capacity (a measurement of functional activity of HDL cholesterol) was independently associated with increased CIMT and CHD after adjusting for conventional risk factors, including HDL cholesterol or apolipoprotein A-1 concentrations (Fig. 7) . Importantly, HDL plasma levels only explained 40% of the cholesterol efflux capacity (88) . Similarly, HDL was noted to have reduced anti-inflammatory capacity in the setting of acute coronary syndromes (89) . Diabetes mellitus and hypertension. After previous data demonstrating improved outcomes for patients with newly diagnosed or longstanding diabetes with intensive risk factor control, a study involving Ͼ3,000 subjects evaluated the hypothesis that screening for early detection of diabetes followed by intensive multifactorial therapy would lead to improved prognosis. After a mean follow-up of 5.3 years, the intensive approach resulted in improvements in risk factor control but nonsignificant reductions in mortality and incident cardiovascular events (90) . Following on the potential harms associated with tight blood pressure control in established diabetes, previously shown in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study, a meta-analysis of randomized trials including Ͼ37,000 patients reported that lowering systolic blood pressure to Յ135 mm Hg (in comparison with Յ140 mm Hg) was associated with a 10% reduction in mortality, 17% reduction in stroke, 20% increase in serious adverse effects, and no differences in other microvascular and macrovascular outcomes. Lowering levels to Ͻ130 mm Hg continued to reduce risk of stroke only, at the expense of a 40% rate of serious adverse events (91) . Similar findings may also apply to another high-risk subgroup of patients, those with established atherothrombosis, in whom reductions of blood pressure to Ͻ130/80 mm Hg provided cerebrovascular and renal but not cardiac protection in a post-hoc analysis of a large trial (92) . The ACCORD study also randomly assigned patients with type 2 diabetes to intensive or standard glucose-lowering therapy, and was stopped prematurely after 3.5 years because of increased mortality in the intensive arm. (93) . Regarding the optimal oral glucoselowering therapy for diabetes, a Danish nationwide study including Ͼ107,000 participants followed up for a median of 3.3 years pointed to increased cardiovascular risk with most sulphonylureas in comparison with metformin when used as single therapy (94) . Antithrombotic therapy. Further evidence became available on the safety of combining clopidogrel and proton pump inhibitors for myocardial infarction survivors, regardless of CYP2C19 genotype (95) . Persistently high platelet reactivity under clopidogrel therapy is associated with recurrent events after percutaneous revascularization. The GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact on Thrombosis and Safety) study randomly allocated 2,214 patients with high residual platelet reactivity to a clopidogrel 600-mg loading dose plus 150 mg daily thereafter or to a standard dose (75 mg daily). High-dose clopidogrel failed to reduce the 6-month incidence of cardiovascular death, nonfatal myocardial infarction, or stent thrombosis (96) . In a separate cohort and despite intensification of antiplatelet therapy based on reactivity tests, event rates remained almost double in patients with residual high platelet reactivity (97) . Higher doses of clopidogrel (225 mg daily) were able to reduce platelet reactivity to normal levels in carriers of CYP2C19 loss-of-function variants, but whether that translates into clinical benefit remains unknown (98) . The multinational PLATO (Platelet Inhibition and Patient Outcomes) trial previously showed that ticagrelor outperformed clopidogrel in preventing recurrent events and death after among patients with coronary syndromes. The reasons for lower beneficial effects in North America remain incompletely understood, although a higher maintenance dose of aspirin in the United States may be partly responsible. Aspirin inhibits prostacyclin in a dosedependent manner, and since prostacyclin probably potentiates P2Y 12 antagonists synergically, this inhibition may lead to reduced antiplatelet activity at higher aspirin doses, particularly for ticagrelor, the most potent P2Y 12 blocker (99). Although beyond the scope of this review, novel factor Xa inhibitors that do not require routine blood monitoring compared favorably to warfarin for patients with atrial fibrillation. However, when these and other novel antithrombotic agents have been added to standard antiplatelet therapy after an acute coronary syndrome, there have been increased bleeding rates without clear atherothrombotic protection (100 -102) . The exception came from the AT-LAS ACS 2-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 51) study, where Ͼ15,000 patients with an acute coronary syndrome were randomly allocated 1:1:1 to rivaroxaban 5 mg per 12 h, rivaroxaban 2.5 mg per 12 h, or placebo (103) . After a mean follow-up of 13 months, rivaroxaban decreased major events by 16% in comparison with placebo (p ϭ 0.008). Additionally, the lower dose also resulted in 34% and 32% reductions in cardiovascular and all-cause mortality, respectively (p ϭ 0.002 for both) (Fig. 8 ). Major and minor bleeding increased with rivaroxaban, although fatal bleeding rates were not significantly different.
Conclusions
The year 2011 brought both promising developments and sobering realizations regarding epidemiology, diagnosis, and management of cardiovascular risk factors and atherothrombotic CVD. The most important findings are summarized in Table 2 . 
